<ul>
<li>3 家投資超過 1000 億美元的頂級製藥公司股票</li>
</ul>
<p>諾華製藥 (NYSE:NVS - 免費報告) - Zacks Research 的投資分析師在 9 月 4 日星期四向投資者發佈的報告中上調了諾華 2027 財年的每股收益 (EPS) 預期。Zacks Research 分析師團隊現在預計該公司將實現每股收益 10.13 美元，高於之前預測的 10.08 美元。諾華當前全年的共識預期收益為每股 8.45 美元。</p>
<p>諾華 (NYSE:NVS - 獲取免費報告) 最近在 7 月 17 日星期四發佈了季度財報。該公司報告季度每股收益 (EPS) 為 2.42 美元，超出分析師共識預期的 2.38 美元，超過 0.04 美元。諾華的股本回報率為 41.08%，淨利潤率為 25.64%。該季度的收入為 140.5 億美元，而分析師預期為 139.4 億美元。在去年同期，該公司每股收益為 1.97 美元。與去年同期相比，該季度的收入增長了 12.3%。</p>
<ul>
<li>3 只可能在市場波動後飆升的動量股票</li>
</ul>
<p>其他一些股票分析師也對 NVS 發佈了報告。摩根士丹利將諾華的評級從 “減持” 上調至 “持平”，並在 8 月 8 日星期五的研究報告中設定了 123.00 美元的目標價。德意志銀行在 8 月 21 日星期四的研究報告中重申了對諾華股票的 “買入” 評級。最後，華爾街 Zen 在 8 月 22 日星期五的研究報告中將諾華的評級從 “強力買入” 下調至 “買入”。一位分析師給予該股票 “強力買入” 評級，一位給予 “買入” 評級，五位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat.com 的數據，諾華目前的共識評級為 “持有”，共識目標價為 124.33 美元。</p>
<p><strong>查看我們關於 NVS 的最新研究報告</strong></p>
<h2>諾華股票表現</h2>
<ul>
<li>製藥領軍企業盈利超預期，但股價下跌</li>
</ul>
<p>NYSE NVS 的股票在星期五開盤價為 128.49 美元。該股票的 50 日移動平均價格為 121.06 美元，200 日移動平均價格為 114.94 美元。該公司的債務與股本比率為 0.53，速動比率為 0.62，流動比率為 0.82。該公司的市值為 2714.1 億美元，市盈率為 18.70，PEG 比率為 1.80，貝塔值為 0.63。諾華的 1 年最低價為 96.06 美元，1 年最高價為 129.21 美元。</p>
<h2>機構投資者對諾華的看法</h2>
<p>對沖基金和其他機構投資者最近對該公司的持倉進行了調整。GFG Capital LLC 在第二季度收購了諾華的新股份，價值約 26,000 美元。Nexus Investment Management ULC 在第一季度收購了諾華的新股份，價值約 25,000 美元。WPG Advisers LLC 在第一季度收購了諾華的新股份，價值約 25,000 美元。Tsfg LLC 在第一季度將其在諾華的股份增加了 366.0%。Tsfg LLC 現在擁有該公司 233 股股票，價值 26,000 美元，此前在此期間又購買了 183 股。最後，Legacy Investment Solutions LLC 在第二季度收購了諾華的新股份，價值約 30,000 美元。13.12% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於諾華</h2>
<p>(獲取免費報告)</p>
<p>諾華製藥 AG 從事醫療保健產品的研究、開發、生產和營銷，業務遍及瑞士及國際市場。該公司為患者和醫生提供處方藥。其重點領域包括心血管、腎臟和代謝、免疫學、神經科學和腫瘤學，以及眼科和血液學。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過諾華</li>
<li>投資建築股票</li>
<li>這就是 Oklo 與其他核創業公司的區別</li>
<li>3 只可以升級您投資組合的家居改善股票</li>
<li>為什麼 Marvell 的 19% 下跌可能是一個重要的買入機會</li>
<li>股息之王寶潔在財報後疲軟時值得買入</li>
<li>Daqo 新能源：太陽能壟斷企業啓動 1 億美元的回購計劃</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元於諾華嗎？</h2>
<p>在您考慮諾華之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而諾華並不在名單上。</p>
<p>儘管諾華目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

諾華制藥

<p>Zacks Research 將諾華製藥 (NYSE:NVS) 的 2027 財年每股收益 (EPS) 預測從 10.08 美元上調至 10.13 美元。目前市場對諾華全年收益的共識預期為每股 8.45 美元。在其最新的季度財報中，諾華報告的每股收益為 2.42 美元，超過了 2.38 美元的預期，收入為 140.5 億美元。分析師對該股票的評級各不相同，整體評級為 “持有”，目標價為 124.33 美元。諾華的股票開盤價為 128.49 美元，市值為 2714.1 億美元</p>

<ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家投資超過 1000 億美元的頂級製藥公司股票</li>
</ul>
</div><p>Novartis AG (NYSE:NVS - Free Report) - Investment analysts at Zacks Research increased their FY2027 earnings per share (EPS) estimates for shares of Novartis in a note issued to investors on Thursday, September 4th. Zacks Research analyst Team now expects that the company will earn $10.13 per share for the year, up from their prior forecast of $10.08. The consensus estimate for Novartis' current full-year earnings is $8.45 per share.</p>
<div class="lb-trans"><p>諾華製藥 (NYSE:NVS - 免費報告) - Zacks Research 的投資分析師在 9 月 4 日星期四向投資者發佈的報告中上調了諾華 2027 財年的每股收益 (EPS) 預期。Zacks Research 分析師團隊現在預計該公司將實現每股收益 10.13 美元，高於之前預測的 10.08 美元。諾華當前全年的共識預期收益為每股 8.45 美元。</p>
</div><p>Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.38 by $0.04. Novartis had a return on equity of 41.08% and a net margin of 25.64%.The business had revenue of $14.05 billion during the quarter, compared to analyst estimates of $13.94 billion. During the same period in the prior year, the company posted $1.97 EPS. The business's revenue for the quarter was up 12.3% compared to the same quarter last year.</p>
<div class="lb-trans"><p>諾華 (NYSE:NVS - 獲取免費報告) 最近在 7 月 17 日星期四發佈了季度財報。該公司報告季度每股收益 (EPS) 為 2.42 美元，超出分析師共識預期的 2.38 美元，超過 0.04 美元。諾華的股本回報率為 41.08%，淨利潤率為 25.64%。該季度的收入為 140.5 億美元，而分析師預期為 139.4 億美元。在去年同期，該公司每股收益為 1.97 美元。與去年同期相比，該季度的收入增長了 12.3%。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能在市場波動後飆升的動量股票</li>
</ul>
</div><p>A number of other equities analysts have also issued reports on NVS. Morgan Stanley raised Novartis from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and set a $123.00 price target for the company in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft reiterated a &#34;buy&#34; rating on shares of Novartis in a research report on Thursday, August 21st. Finally, Wall Street Zen downgraded Novartis from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Novartis presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $124.33.</p>
<div class="lb-trans"><p>其他一些股票分析師也對 NVS 發佈了報告。摩根士丹利將諾華的評級從 “減持” 上調至 “持平”，並在 8 月 8 日星期五的研究報告中設定了 123.00 美元的目標價。德意志銀行在 8 月 21 日星期四的研究報告中重申了對諾華股票的 “買入” 評級。最後，華爾街 Zen 在 8 月 22 日星期五的研究報告中將諾華的評級從 “強力買入” 下調至 “買入”。一位分析師給予該股票 “強力買入” 評級，一位給予 “買入” 評級，五位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat.com 的數據，諾華目前的共識評級為 “持有”，共識目標價為 124.33 美元。</p>
</div><p><strong>View Our Latest Research Report on NVS</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 NVS 的最新研究報告</strong></p>
</div><h2>Novartis Stock Performance</h2>
<div class="lb-trans"><h2>諾華股票表現</h2>
</div><ul>
<li>Pharma Leader Beats on Earnings, But Shares Fall</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥領軍企業盈利超預期，但股價下跌</li>
</ul>
</div><p>Shares of NYSE NVS opened at $128.49 on Friday. The stock has a fifty day moving average price of $121.06 and a two-hundred day moving average price of $114.94. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. The firm has a market cap of $271.41 billion, a P/E ratio of 18.70, a PEG ratio of 1.80 and a beta of 0.63. Novartis has a 1 year low of $96.06 and a 1 year high of $129.21.</p>
<div class="lb-trans"><p>NYSE NVS 的股票在星期五開盤價為 128.49 美元。該股票的 50 日移動平均價格為 121.06 美元，200 日移動平均價格為 114.94 美元。該公司的債務與股本比率為 0.53，速動比率為 0.62，流動比率為 0.82。該公司的市值為 2714.1 億美元，市盈率為 18.70，PEG 比率為 1.80，貝塔值為 0.63。諾華的 1 年最低價為 96.06 美元，1 年最高價為 129.21 美元。</p>
</div><h2>Institutional Investors Weigh In On Novartis</h2>
<div class="lb-trans"><h2>機構投資者對諾華的看法</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. GFG Capital LLC acquired a new stake in shares of Novartis in the second quarter valued at about $26,000. Nexus Investment Management ULC bought a new stake in shares of Novartis in the first quarter valued at about $25,000. WPG Advisers LLC bought a new stake in shares of Novartis in the first quarter valued at about $25,000. Tsfg LLC lifted its stake in shares of Novartis by 366.0% in the first quarter. Tsfg LLC now owns 233 shares of the company's stock valued at $26,000 after buying an additional 183 shares during the period. Finally, Legacy Investment Solutions LLC bought a new stake in shares of Novartis in the second quarter valued at about $30,000. 13.12% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近對該公司的持倉進行了調整。GFG Capital LLC 在第二季度收購了諾華的新股份，價值約 26,000 美元。Nexus Investment Management ULC 在第一季度收購了諾華的新股份，價值約 25,000 美元。WPG Advisers LLC 在第一季度收購了諾華的新股份，價值約 25,000 美元。Tsfg LLC 在第一季度將其在諾華的股份增加了 366.0%。Tsfg LLC 現在擁有該公司 233 股股票，價值 26,000 美元，此前在此期間又購買了 183 股。最後，Legacy Investment Solutions LLC 在第二季度收購了諾華的新股份，價值約 30,000 美元。13.12% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Novartis</h2>
<div class="lb-trans"><h2>關於諾華</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>諾華製藥 AG 從事醫療保健產品的研究、開發、生產和營銷，業務遍及瑞士及國際市場。該公司為患者和醫生提供處方藥。其重點領域包括心血管、腎臟和代謝、免疫學、神經科學和腫瘤學，以及眼科和血液學。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>Investing in Construction Stocks</li>
<li>Here's What Separates Oklo From the Rest of the Nuclear Startups</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Why Marvell’s 19% Drop Could Be a Big Buy-the-Dip Opportunity</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>Daqo New Energy: Solar Monopoly Launches $100M Buyback</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過諾華</li>
<li>投資建築股票</li>
<li>這就是 Oklo 與其他核創業公司的區別</li>
<li>3 只可以升級您投資組合的家居改善股票</li>
<li>為什麼 Marvell 的 19% 下跌可能是一個重要的買入機會</li>
<li>股息之王寶潔在財報後疲軟時值得買入</li>
<li>Daqo 新能源：太陽能壟斷企業啓動 1 億美元的回購計劃</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於諾華嗎？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮諾華之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而諾華並不在名單上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管諾華目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Zacks Research 上調了諾華製藥 2027 財年的每股收益預測